Cash and cash equivalents, as of December 31, 2025, were $119.7 million compared to $102.7 million as of December 31, 2024. Based on current operating plans, the Company expects that its existing cash and cash equivalents, as of December 31, 2025, together with proceeds from the follow-on equity offering in February 2026, will be sufficient to fund operations into Q1 2028.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Announces Equity Offering to Fund CAN-2409
- Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
- Candel Therapeutics announces $100M royalty funding agreement
- Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
- Candel Therapeutics announces $100M common stock offering